



ALAN S. KLIGER MD

Chair, NTDS Initiative

Dr. Kliger is a Clinical Professor of Medicine, Yale University School of Medicine, and Vice President, Medical Director of Clinical Integration, Yale New Haven Health System. He is a member of the Renal Standing Committee for the National Quality Forum, and serves on the Board of Directors of the Kidney Health Initiative, a partnership between the FDA, ASN, industry and academic nephrology. He served formerly as Senior Vice President Medical Affairs, Chief Quality Officer, Yale New Haven Health System and Senior Vice President, Chief Medical Officer, Chief Quality Officer Hospital of Saint Raphael, New Haven Connecticut.

Dr. Kliger is a past president of the Renal Physicians Association, and serves on its Quality, Safety and Accountability Committee. He is a past president of the Forum of ESRD Networks. He served as chair of the steering committee for the NIH Frequent Hemodialysis Study, a national prospective randomized study of in-center daily and home nocturnal hemodialysis, and currently chairs the steering committee for an NIH/NIDDK Consortium on Novel Therapies for Hemodialysis Patients.

Relevant Publications

Publications concerning Infections in Peritoneal Dialysis

1. Kiernan L, Finkelstein FO, **Kliger AS**, Gorban-Brennan N, Juergensen P, Mooraki A, Brown E. Outcome of polymicrobial peritonitis in continuous ambulatory peritoneal dialysis patients. *Am J Kid Dis* 3:461-464, 1995.
2. Goldie SJ, Kiernan-Troidle L, Torres MD, Gorban-Brennan N, Dunne D, **Kliger AS**, Finkelstein FO. Fungal Peritonitis in a Large Chronic Peritoneal Dialysis Population: A Report of 55 Episodes. *Amer J Kid Dis* 28:86-91, 1996.
3. Troidle L, **Kliger AS**, Goldie S, Gorban-Brennan N, Brown E, Fikrig M, Finkelstein FO. CPD Associated Peritonitis of Nosocomial Origin. *Peritoneal Dialysis International* 16:505-510, 1996.
4. Troidle L, **Kliger AS**, Gorban-Brennan N, Fikrig M, Golden M, Finkelstein FO. Nine Episodes of CPD-associated peritonitis with Vancomycin Resistant Enterococci. *Kidney International* 50:1368-1372, 1996.
5. Troidle LK, Gorban-Brennan N, **Kliger AS**, Finkelstein FO. Differing Outcomes of Gram-positive and Gram-negative Peritonitis. *Amer J Kidney Disease* 32:623-628. 1998.
6. Troidle LK, Gorban-Brennan N, **Kliger AS**, Finkelstein FO. Peritonitis in the Extended Care Facility. *Advances in Peritoneal Dialysis* 14:127-130, 1998
7. Troidle LK, Gorban-Brennan N, **Kliger AS**, Finkelstein FO. Continuous Cycler Therapy, Manual Peritoneal Dialysis Therapy and Peritonitis. *Advances in Peritoneal Dialysis* 14:137-141, 1998.
8. Troidle L, Gorban-Brennan N, **Kliger AS**, Finkelstein FO. The Effect of Duration of Chronic PD Therapy on the Development of Peritonitis. *Perit Dial International* 19:376-379, 1999

9. Troidle L, **Kliger AS**, Finkelstein FO. Challenges of Managing CPD-Peritonitis. *Peritoneal Dialysis International* 19:315-318, 1999
10. Troidle L, Gorban-Brennan N, **Kliger AS**, Finkelstein FO. Once Daily Intraperitoneal Cefazolin and Oral Ciprofloxacin as Empiric Therapy for the Treatment of Peritonitis. *Advances in Peritoneal Dialysis* 15:213-216, 1999.
11. Cary HB, Troidle L, **Kliger AS**, Finkelstein FO. VRE Peritonitis: A Case Report and Review of the Literature. *Seminars in Dialysis* 12:333-335, 1999.
12. Troidle L, **Kliger AS**, Finkelstein FO. Challenges of managing peritonitis. *Perit Dial Int* 19:315-318, 1999
13. Allen JR, Troidle LK, Juergensen PH, **Kliger AS**, Finkelstein FO. Incidence of peritonitis in chronic peritoneal dialysis patients infused with intravenous iron dextran. *Perit Dial Int* 20:674-678, 2000
14. Troidle L, Watnik S, Wuerth DB, Gorban-Brennan N, **Kliger AS**, Finkelstein FO. Depression and Its Association with Peritonitis in Long-Term Peritoneal Dialysis Patients. *American Journal of Kidney Diseases*. August 2003 42(2):350-354.
15. Troidle L, Gorbann-Brennan N, **Kliger AS**, Finkelstein FO. Continuous Peritoneal Dialysis Associated Peritonitis: A Review and Current Concepts. *Seminars in Dialysis* November-December 2003 16(6):428-437.
16. Troidle L, **Kliger A**, Gorban-Brennan N, Finkelstein F. Course of C-reactive protein during continuous peritoneal dialysis-associated peritonitis. *Nephrology*. 2005 Oct;10(5):442-5

Publications concerning infections in hemodialysis

1. DeOreo PB, **Kliger AS**. *Serratia liquefaciens* infections at a hemodialysis center. *N Engl J Med*. 2001 Sep 20;345(12):91; author reply 922-3.
2. Khaled GH, Finkelstein FO, Carey HB, Wardlaw SC, **Kliger AS**, Edberg SC. Method for studying development of colonization and infection of dialysis catheters. *Adv Perit Dial*. 2001;17:163-7

Publications concerning Quality and Safety in Dialysis

1. **Kliger AS**. Clinical Practice Guidelines and Performance Measures in ESRD. *Amer J Kidney Disease* 32:5173-5176, 1998.
2. **Kliger AS**, Haley WE. Clinical Practice Guidelines in End Stage Renal Disease: A Strategy for Implementation. *J Amer Soc Neph* 10:872-877, 1999.
3. **Kliger AS**. Improving the quality of care in dialysis facilities: a model for accountability. *Dialysis & Transplantation* 2:5, 2000
4. **Kliger AS**, Diamond LH. Patient safety in end-stage renal disease: How do we create a safe environment? *Adv Ren Replace Ther* 8:131-137, 2001
5. **Kliger AS**. Serum Albumin Measurement in Dialysis Patients: Should It Be A Measure of Clinical Performance? *Journal of Renal Nutrition* 12(3):July, 2002
6. Diamond, LH, **Kliger AS**, Goldman RS, Palevsky PM. Quality Improvement Projects: How Do We Protect Patients Rights? *American Journal of Medical Quality*. Jan-Feb. 2004, 19(1):25-27
7. **Kliger AS**. Patient safety in the dialysis facility. *Blood Purif*. 2006; 24 (1):19-21

8. Himmelfarb J, **Kliger AS**. End-Stage Renal Disease Measures of Quality. Annual Review of Medicine, 58:387-399, February 2007
9. **Kliger AS**: The Dialysis Medical Director's Role in Quality and Safety. Seminars in Dialysis 2007 May-Jun;20 (3), 261-4
10. **Kliger AS**, Fishbane S, Finkelstein FO. Erythropoietic Stimulating Agents and Quality of a Patient's Life: Individualizing Anemia Treatment. Clin J Am Soc Nephrol. 2012 Feb 7(2):354-35
11. Garrick R, **Kliger A**, Stefanchik B. Patient and facility safety in hemodialysis: Opportunities and strategies to develop a culture of safety. Clin J Am Soc Nephrol 7(4): 680–688, 2012. doi: 10.2215/CJN.06530711
12. Finkelstein FO, Yalamanchili HB, **Kliger AS**. Patient perceptions and experiences of ESRD care: quality and satisfaction. Am J Kidney Dis. 2013 Mar;61(3):366-7. doi:10.1053/j.ajkd.2012.12.011
13. **Kliger AS**; Maintaining Safety in the dialysis facility Clin J Am Soc Nephrol 10: 688–695, 2015. doi: 10.2215/CJN.08960914
14. **Kliger AS**. Quality Measures for dialysis: Time for a balanced scorecard. Clin J Am Soc Nephrol. 2016 Feb 5;11(2):363-368. doi: 10.2215/CJN.06010615 Epub 2015 Aug 27